The most frequently used mpox vaccine provides partial immunity to the disease but isn’t always able to prevent severe symptoms or disease transmission. A new vaccine candidate from Moderna, mRNA-1769, more effectively limits symptoms and disease duration in primates that were infected with a lethal strain of the mpox virus when compared to a currently licensed modified vaccinia Ankara (MVA) vaccine. The study was published September 4 in the journal Cell.
Investigational mpox mRNA vaccine more effectively reduces disease severity in primates compared to available vaccines
